This is a routine inducement grant for a new hire with no immediate read-through for the stock. Monitor upcoming clinical data readouts for ficerafusp alfa in head and neck squamous cell carcinoma.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $8.89entry
- T+1 · 12d ago −7.87%α −3.46% · $8.19
- T+5 · 6d ago +18.45%α +19.36% · $10.53
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Bicara Therapeutics granted a new employee a non-qualified stock option to purchase 50,000 shares at $7.93 per share as a material inducement to employment under its 2026 Inducement Plan. The award is routine and immaterial relative to the company's market cap of $604M.
Key Facts
- One new employee received a non-qualified stock option to purchase 50,000 shares at $7.93 per share.
- Exercise price equals the November 2, 2026 closing price of $7.93.
- Options vest over four years: 25% on first anniversary, then quarterly over three years.
- Grant was approved by the compensation committee as a material inducement under Nasdaq Listing Rule 5635(c)(4).
Financial Impact
50,000 shares at $7.93 exercise price; maximum potential dilution of ~0.07% of outstanding shares based on market cap of $604M and stock price of $7.93.
Risk Factors
- No material risk from this grant; standard equity compensation for a new employee.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395298 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Viewing Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers